The stock's fall snapped a two-day winning streak.

We recently compiled a list of the Top 10 Stocks to Buy According to Lee Munder Capital Group. In this article, we are going ...

AbbVie has entered a partnership and option-to-license agreement with Xilio for tumour-activated, antibody-based ...

We recently compiled a list of the Jim Cramer Shed Light on These 8 Stocks Recently. In this article, we are going to take a ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

AbbVie reported strong Q4 results, driven by Skyrizi, Rinvoq, neuroscience products, and eye care. Click here to find out why ...

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the twenty-four ratings firms that are presently covering the stock, Marketbeat.com ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.

Shares in biotech group Xilio Therapeutics ($XLO) surged over 125% today after it sealed a cancer-fighting deal with AbbVie ...

AbbVie Inc.’s stock rose 5% early Friday to lead S&P 500 gainers premarket, after the drug company beat fourth-quarter ...